Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT06087757
PHASE2

Clemastine Treatment in Individuals With Williams Syndrome

Sponsor: Sheba Medical Center

View on ClinicalTrials.gov

Summary

This study explores the neurobiological etiology of Williams syndrome and potential therapeutic targets for associated social, motor, and cognitive abnormalities. The main translational objective will be to test the effectiveness of Clemasntine on neurocognitive and other associated abnormalities in individuals with Williams syndrome.

Official title: Clemastine Treatment in Individuals With Williams Syndrome- a Double-blind Placebo Control to Assess the Safety and Efficacy

Key Details

Gender

All

Age Range

6 Years - 30 Years

Study Type

INTERVENTIONAL

Enrollment

30

Start Date

2024-04-01

Completion Date

2026-07

Last Updated

2026-03-06

Healthy Volunteers

No

Interventions

DRUG

Open Label Clemastine with a blinded randomize withdrawal

Clemastine will be given in doses as the maximum dose recommended for allergy condition. Age 6-12 years 4.02 mg/day, age 12-30 years 8.04 mg/day.

Locations (2)

Child and Adolescent Psychiatry Unit, Sheba Medical Center

Ramat Gan, Israel

Tel Aviv University

Tel Aviv, Israel